Ignoring threats by communal forces, IAS topper Tina Dabi weds her Muslim friend

Bengaluru, Jun 30: Private medical colleges in Bengaluru have agreed to join hands with the Karnataka government for the treatment of COVID-19 patients.

The representatives from private medical colleges have promised the state government to provide 2000 beds immediately and another 4500 beds will be added within a week.

The development took place as Chief Minister BS Yediyurappa on Tuesday held a second round of meeting with representatives of private hospitals at Vidhana Soudha over COVID-19. 

The Chief Minister and Medical Education Minister Dr K Sudhakar held separate meetings with the representatives from private colleges administration and all the private colleges have assured to extend their support to the government decision. 

"There are 11 private and three government medical colleges in the city and we will get about 6500 beds from these for COVID treatment," Dr Sudhakar informed media after the meeting.

He further said, "These facilities including doctors and staff will be made available to the government within a week and the beds will be allocated to COVID patients through BBMP's centralised system. The insurance facility will be extended to the doctors and staff serving in these private hospitals also."

PG students in private medical colleges and other staff will be utilised in COVID Care Centres, the minister said.

"There will be some changes in the treatment protocols going forward. The decision regarding this will be taken in the meeting that will be held in the evening under the chairmanship of the CM," the minister explained.

According to him, symptomatic patients, persons aged above 60 years and those with comorbidities like diabetes, hypertension and serious kidney, liver, lungs and heart-related ailments will be admitted to hospitals. 

Other asymptomatic persons will be monitored in COVID care centres. Detailed notification with these guidelines will be released tomorrow, the minister said.

The meeting was chaired by CM BS Yediyurappa and Deputy CM Ashwatnarayana, Ministers Basavaraj Bommai, R Ashoka and senior officials were also present.

Kasaragod, Apr 2: Kerala reported 21 new cases of coronavirus with eight from the worst affected Kasaragod district, taking the tally of active patients to 256, Chief Minister Pinarayi Vijayan said on Thursday.

Besides, Kasaragod, five positive cases have been detected from Idukki, two from Kollam and one each from Thiruvananthapuram, Pathnamthitta, Thrissur, Malappuram, Kozhikode and Kannur, he told reporters here.

At least 1.65 lakh people are under survillence in the state, 643 in various hospitals.

Presently, 256 people are under treatment for the virus in the state where two fatalities have occurred, Vijayan said.

Bengaluru, Mar 28: Sun Tsu, in 'The Art of War' speaks of a skilful general who can subdue his enemy without any fighting. This constitutes the ultimate triumph which is referred to as stratagem. Today, we would need one such when we are faced with the '21-day corona challenge' for India.
Nearly four weeks back, Dr Jyothsna Rao, Dr Gururaj Rao and I sat across the OPD in the afternoon at HCG Bengaluru discussing our ongoing cancer immunology research. While on this topic, we drifted into the discussion on the coronavirus. During this engaging discussion, we wondered the similarity of the enigma between the virus and cancer. I paused to ask Dr Jyothsna and Dr Guru - how we wish we could do something against this virus.
Dr Jyothsna is a PhD from NCBS and had worked under Dr Ralph Steinman, physician and researcher from Rockefeller University, who won the Nobel Prize for his discovery of the dendritic cell and its role in adaptive immunity in 2011. Dr Gururaj is a molecular and cell biologist who did his PhD at the Chapel Hill, University of North Carolina and is the Director of iCrest.
Jyothsna while hearing our perplexing conversation on the covid intervened, "Yes, surely. I think we should take a break from cancer and focus on the innate and adaptive immunity role in COVID-19."
Thus began this sincere attempt to relook the human immune system from the eyes of the COVID-19.
We have 10 types of immune cells at the least which are widely dispersed in millions across the body. When our body is invaded by a foreign organism (bacteria, fungi or virus), these cells work with each other to destroy the invader.
Now, the question is - how do the immune cells talk to each other? They use small-molecule substances called cytokines (cyto means cells; kine means movement). There are many cytokines that are involved in work on the immune system. The most relevant for viruses are interferons.
Interferons (IFN) as the name reflects have an ability to interfere with the viral activity and stop their multiplication. These specialised signal proteins are released by our cells in response to a viral attack to forewarn other cells. They help build the antiviral proteins within the cells to kill the virus as it tries to invade the new cells.
Historically, interferons are a group of cytokines known to be potent antiviral agents against viruses and a hallmark cytokine induced by the host upon viral infections. Interferons possess unique immunoregulatory activities and are signature cytokines released by (TH1) T immune cells, which are crucial in viral infections.
As the outbreak of COVID-19 grapples us, an urgent need for finding strategies to combat the virus is growing. Coronaviruses (CoVs) are a group of RNA viruses. In patients infected with coronavirus, it was indicated that the activation of the IFN does not occur until 48 hours post-infection. Thus the delayed IFN-related antiviral response by the healthy cells leads to coronavirus evade the immune response.
Numerous studies have presented the success in defeating CoVs by the direct administration of IFNs. In a combination as a concoction, it was shown to synergistically inhibit the virus replication in vitro.
Moreover, it is understood that the earlier induction of IFNs in children although they have a less developed immune system could be the reason behind the children being least affected.
The key to success in reducing the disease fatality might be the stimulation of the immune responses to trigger IFN production at the very early stages of the disease, which might be done through the administration of IFN. Despite the evidence for the efficacy of IFNs in treating CoV-induced infections, the proper dosing and ideal timing for such interventions needs to be verified in clinical trials.
For the later stages of the diseases in advance stages where patients are on ventilator and have developed respiratory distress, we propose to utilise the mesenchymal cells derived from donor bone marrow that have been known to treat acute respiratory syndrome. Mesenchymal cells are known to possess anti-inflammatory activity and thus used often in autoimmune diseases.
With this scientific background, we have activated T cells from healthy donors, in a cGMP facility at iCrest - HCG hospital with an enriched cocktail of cytokines rich in Interferons. Injections of this cocktail we believe will result in a surge of cytokines in the body of the infected person and will boost his ability to fight the virus in the early phases. We are in the initial phases of this study and hope to be ready in the coming weeks with meaningful data on its potential utility.
Currently, it awaits government approvals (Union and state) and we have applied to central drugs authority for their initial evaluation and further directions.
As my Guru often expounded the philosophy of 'Seva' - the goal of education is knowledge, the end goal of knowledge is service. In this attempt to serve our fellow humans at this brink of unprecedented crisis, medical fraternity stands with you and promises to do our best for your safety.
We assure to exhaust every bit of our spirit in this fight against coronavirus. We have lost the sight of shores and travelled thus far, but that is the mandatory first step to cross the ocean. Are we going to succeed in this battle, is something only time will answer.